Imprimis Pharmaceuticals, Inc. "A Unique Approach to 505(b)(2)" July 2013 Mark L. Baum, C.E.O. 1 Safe Harbor Statement This presentation contains "forward-looking statements" as defined in the Private Securities Litigati

Imprimis Pharmaceuticals, Inc.

"A Unique Approach to 505(b)(2)"

Mark L. Baum, C.E.O.

Safe Harbor Statement

This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act

of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on

current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or

uncertainties materialize, actual results could vary materially from our expectations and projections.

Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include

the difficulties related to the Company's ability to obtain regulatory approval to market Impracor , capitalize on

its perceived potential benefits arising from its relationship with Professional Compounding Centers of America,

Inc., leverage compounded generic drugs to create a development pipeline and otherwise pursue its business

plan, and leverage its Accudel technology in the development of potential product candidates. In addition, the

outcome of the final analyses of the data from the past and future Phase 3 clinical trial may vary from the

Company's initial conclusions, the FDA may not agree with the Company's interpretation of such results or may

challenge the adequacy of the Company's future Impracor clinical trial design or the execution of the same clinical

trials, the FDA may require the Company to complete additional clinical trials for Impracor before the Company

can submit a 505(b)(2) NDA application, the results of any future clinical trials may not be favorable and the

Company may never receive regulatory approval for Impracor , the Company may be unable to raise additional

funding to complete its product development plans, or be unable to acquire, develop or commercialize new

products and or enter into strategic alliances and transactions. Other risks include uncertainties inherent in pre-

clinical studies and clinical trials, difficulties in conducting its clinical trials, unexpected new data, safety and

technical issues, competition and market conditions. More detailed information about the Company and the risk

factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the

Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on

Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the

date hereof, given these risks and uncertainties. All forward-looking statements are qualified in their entirety by

this cautionary statement and the Company undertakes no obligation to revise or update any forward-looking

statements as a result of new information or future events or developments.

Imprimis Pharmaceuticals, Inc. | *

Imprimis Pharmaceuticals, Inc. | *

Imprimis Pharmaceuticals, Inc. | *

Approx. $19.0M in cash as of 03/31/13

Nominal debt; no preferred instruments

Phase 3 topical NSAID pivotal to start in Q3 2013

Exclusive commercial rights to PCCA development IP

10,000+ drug formulations

10+ drug delivery technologies

Vast market "unmet need" database

Exclusive access to review PCCA member IP

Experienced science and management teams

Imprimis Pharmaceuticals, Inc. | *

505(b)(2) Lower Risk | Higher Margin

Our mission is to develop proprietary drugs using the

FDA 505(b)(2) drug development pathway

Less Development Time & Lower Cost

505(b)(2) products can have Orange Book-listed patents, can enjoy 30-month protection against

generic competitors; NCE (5 yrs); Orphan Drug (7 yrs); Pediatric Extension (6 mos.)

505(b)(2) Development Budget Comparison: $2-7M versus $100M+ for (b)(1)

Imprimis Pharmaceuticals, Inc. | 6

Imprimis Development Model

Imprimis Pharmaceuticals, Inc. | *

Imprimis Brings Innovation

from Pharmaceutical Compounders

to the >$300B U.S. Pharmaceutical Industry

PCCA Strategic Relationship

Professional Compounding Centers of America

(PCCA) is the largest compounding pharmacy

organization in North America

1. Supply chemicals, equipment, accredited training, software,

and business/pharmacy consulting assistance

Over 4,000 pharmacy businesses/chains worldwide

PCCA relationship gives Imprimis exclusive access to:

1. Proprietary and proven drug formulations

2. Proprietary and proven drug delivery technologies

(Lipoderm and others)

3. Market data (>100,000 inbound calls per year)

4. Analytics (Eagle Analytics)

5. Exclusive access to review PCCA member IP

Our strategic relationship is exclusive

PCCA invested $4M into Imprimis at $4.80 per share

Proprietary Drug Pipeline

Imprimis Pharmaceuticals, Inc. | *

Imprimis Pharmaceuticals, Inc. | *

Drive Shareholder Value

Monetize vast 505(b)(2)

Selectively internal

Improve Patient Care

Novel drug administration

negative side effect

Increase therapeutic

Monetizing the PCCA Relationship

Step 1: Opportunity Matrix

X-Axis: Drug Administration

Reimbursement Landscape

Partner, Out-License

Imprimis Growth & Development Process

Out-License or Develop

Market Launch/Partner

Imprimis Pharmaceuticals, Inc. | *

Imprimis Pharmaceuticals, Inc. | *

Additional compounds in late stage assessment are in the therapeutic areas of

Pain and Sexual Dysfunction

Improving Patient Care:

Imprimis Pharmaceuticals, Inc. | *

The Topical NSAID Market

Imprimis Pharmaceuticals, Inc. | 15